- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03961347
Lactobacillus Johnsonii Supplementation in Adults With T1D
August 7, 2023 updated by: University of Florida
Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity.
The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
57
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael Haller, MD
- Phone Number: 352-273-9264
- Email: hallemj@peds.ufl.edu
Study Contact Backup
- Name: Sarah Peeling, BS
- Phone Number: 352-273-5275
- Email: smpeeling@peds.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- UF Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have confirmed T1D by physician diagnosis
- Have normal values at screening for CBC and complete metabolic profiles (with the exception of fasting glucose and HbA1c).
- Are able to swallow a capsule.
- Are willing to complete weekly online questionnaires.*
- Are willing to consume a probiotic or placebo capsule daily for 24 weeks.
- Are willing to provide stool samples throughout the study.
- Are willing to provide blood samples throughout the study.
- Are willing to take three 2-hour Mixed-Meal Tolerance Tests (MMTTs).
Are able to access a computer with Internet throughout the study.*
- Note: Going into the study, we want the participants to have daily internet access. However, if this changes once they are in the study, we will provide paper copies of the questionnaires.
Exclusion Criteria:
- Have had or are currently being treated for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's, ulcerative colitis, etc.).
- Have chronic disease kidney disease.
- Have had or are currently being treated for other immune-compromising diseases or conditions (HIV, AIDS, hepatitis, cancer, leukemia, transplant patient, Lupus, DiGeorge syndrome, selective deficiency of IgA, Bruton's disease etc.).
- Have an underlying structural heart disease.
- Currently live with an immunocompromised person.
- Are currently taking medications for constipation and/or diarrhea.
- Have taken antibiotics within the past 2 weeks prior to randomization.
- Are currently taking a probiotic supplement and are unwilling to discontinue it a minimum of 2 weeks prior to the study start.
- Are a current smoker.
- Are currently pregnant or lactating or a female who plans to become pregnant in the next 6 months.
- Have a known allergy to milk or milk protein.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Probiotic Group
The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs.
Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
|
Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
|
Placebo Comparator: Placebo Group
The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic).
Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
|
Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)
Time Frame: 52 weeks
|
CBC and CMP will be evaluated at four different time points during study: 1st measure will be at screening visit and before starting intervention (visit 1/week -4, baseline period), 2nd measure will be after 12 weeks after starting intervention (visit 2/ week 12), 3rd measure will be after the 24 weeks of intervention (visit 3/ week 24) and the 4th measure will be 24 weeks later, end of washout period (visit 4/week 48).
Values should be within the normal range except for glucose.
|
52 weeks
|
Tolerance will be evaluated according to their responses on weekly questionnaires
Time Frame: 52 weeks
|
The weekly questionnaire will ask participants to respond to questions regarding their gastrointestinal health (bowel movement frequency, gastrointestinal and other symptoms (i.e., constipation, diarrhea, stomach pain) and general wellness (if you consumed an antibiotic, visited a doctor, etc.).
The questionnaires follow a scale from 1-7, 1 = No discomfort at all, 7 = Very severe discomfort.
|
52 weeks
|
Adverse Event and/or Serious Adverse Event
Time Frame: 24 weeks
|
Adverse Event and/or Serious Adverse Event will be recorded daily by parents and notified to investigator within 24 hrs., in particular gastro-intestinal symptoms, fever and rashes.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Haller, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2020
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
May 22, 2019
First Submitted That Met QC Criteria
May 22, 2019
First Posted (Actual)
May 23, 2019
Study Record Updates
Last Update Posted (Actual)
August 9, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201901428 -N
- OCR22502 (Other Identifier: UF OnCore)
- 1R01DK121130-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes (T1D)
-
University of FloridaJuvenile Diabetes Research FoundationRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Recruiting
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
National Institute of Allergy and Infectious Diseases...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Clinical...CompletedType 1 Diabetes (T1D) | Islet TransplantationUnited States
-
McGill University Health Centre/Research Institute...Not yet recruitingHealthy Subjects | Type 1 Diabetes (T1D)
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
Clinical Trials on L. johnsonii Probiotic
-
University of FloridaJuvenile Diabetes Research FoundationRecruiting
-
China Medical University HospitalCompleted
-
University of FloridaJuvenile Diabetes Research FoundationCompleted
-
University of Sao PauloUniversity of Sao Paulo General HospitalUnknownAsthma OccupationalBrazil
-
Soroka University Medical CenterCompleted
-
BioGaia ABCompletedAtopic DermatitisSouth Africa
-
University of MichiganInstitut RosellCompletedChronic Rhinosinusitis
-
Odense University HospitalUniversity of Southern Denmark; Crohn's and Colitis FoundationCompletedUlcerative ColitisDenmark
-
McMaster UniversityCompletedInfections | Diarrhea | Ventilator Associated Pneumonia | Antibiotic-associated Diarrhea | C-DifficileCanada, United States, Saudi Arabia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Technology Evaluation in the... and other collaboratorsCompletedAntibiotic-Associated Diarrhea | Ventilator Associated Pneumonia (VAP) | Other Infections | C-Difficile | Duration of Mechanical Ventilation | Length of ICU Stay | Length of Hospital Stay | ICU and Hospital MortalityUnited States, Canada